• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抑制骨质疏松症中的骨质流失：科里林（CL）作为治疗剂的潜力。

Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent.

机构信息

Department of Joint Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

The Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China.

出版信息

Aging (Albany NY). 2024 Jun 11;16(11):9569-9583. doi: 10.18632/aging.205885.

DOI:10.18632/aging.205885
PMID:38862240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11210224/
Abstract

The global prevalence of osteoporosis is being exacerbated by the increasing number of aging societies and longer life expectancies. In response, numerous drugs have been developed in recent years to mitigate bone resorption and enhance bone density. Nonetheless, the efficacy and safety of these pharmaceutical interventions remain constrained. Corylin (CL), a naturally occurring compound derived from the anti-osteoporosis plant L., has exhibited promising potential in impeding osteoclast differentiation. This study aims to evaluate the effect and molecular mechanisms of CL regulating osteoclast differentiation and its potential as a therapeutic agent for osteoporosis treatment . Our investigation revealed that CL effectively inhibits osteoclast formation and their bone resorption capacity by downregulating the transcription factors NFATc1 and c-fos, consequently resulting in the downregulation of genes associated with bone resorption. Furthermore, it has been observed that CL can effectively mitigate the migration and fusion of pre-osteoclast, while also attenuating the activation of mitochondrial mass and function. The results obtained from an study have demonstrated that CL is capable of attenuating the bone loss induced by ovariectomy (OVX). Based on these significant findings, it is proposed that CL exhibits considerable potential as a novel drug strategy for inhibiting osteoclast differentiation, thereby offering a promising approach for the treatment of osteoporosis.

摘要

骨质疏松症在全球的流行率正随着老龄化社会和预期寿命延长而加剧。为应对这一情况，近年来开发了许多药物来抑制骨质吸收并提高骨密度。尽管如此，这些药物干预措施的疗效和安全性仍受到限制。科里林（CL）是一种从抗骨质疏松植物 L. 中提取的天然化合物，在抑制破骨细胞分化方面显示出了有前景的潜力。本研究旨在评估 CL 调节破骨细胞分化的作用和分子机制及其作为骨质疏松症治疗药物的潜力。我们的研究表明，CL 通过下调转录因子 NFATc1 和 c-fos，有效抑制破骨细胞的形成及其骨吸收能力，从而下调与骨吸收相关的基因。此外，还观察到 CL 可以有效抑制破骨前体细胞的迁移和融合，同时减轻线粒体质量和功能的激活。一项 研究的结果表明，CL 能够减轻卵巢切除（OVX）引起的骨丢失。基于这些重要发现，提出 CL 作为一种抑制破骨细胞分化的新型药物策略具有很大的潜力，为骨质疏松症的治疗提供了一种有前途的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/bab5fcb5d1bc/aging-16-205885-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/688e9c5c6552/aging-16-205885-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/4f07068e84ac/aging-16-205885-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/9c0eccb95ae4/aging-16-205885-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/1f4f368c7083/aging-16-205885-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/97c70915bc8b/aging-16-205885-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/1fe6257db284/aging-16-205885-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/df8a75c6193d/aging-16-205885-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/bab5fcb5d1bc/aging-16-205885-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/688e9c5c6552/aging-16-205885-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/4f07068e84ac/aging-16-205885-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/9c0eccb95ae4/aging-16-205885-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/1f4f368c7083/aging-16-205885-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/97c70915bc8b/aging-16-205885-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/1fe6257db284/aging-16-205885-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/df8a75c6193d/aging-16-205885-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5772/11210224/bab5fcb5d1bc/aging-16-205885-g008.jpg

相似文献

1
Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent.抑制骨质疏松症中的骨质流失：科里林（CL）作为治疗剂的潜力。
Aging (Albany NY). 2024 Jun 11;16(11):9569-9583. doi: 10.18632/aging.205885.
2
Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.芫花素 B 通过抑制 NFATc1 和 ROS 活性抑制 RANKL 诱导的破骨细胞生成和去卵巢骨质疏松症。
Theranostics. 2019 Jul 3;9(16):4648-4662. doi: 10.7150/thno.35414. eCollection 2019.
3
Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis.木瓜抑制破骨细胞分化，防止去卵巢诱导的骨质疏松症，其作用机制与抑制 NFATc1 表达有关。
BMC Complement Med Ther. 2020 Feb 5;20(1):35. doi: 10.1186/s12906-020-2841-9.
4
Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.白杨素 A 通过抑制 NF-κB 和 Akt 通路抑制 RANKL 诱导的破骨细胞生成和卵巢切除诱导的骨质疏松症。
J Ethnopharmacol. 2021 Aug 10;276:114176. doi: 10.1016/j.jep.2021.114176. Epub 2021 Apr 30.
5
Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca-NFATc1 and Cav-1 signaling pathways.鸢尾黄素通过抑制 Ca-NFATc1 和 Cav-1 信号通路抑制 RANKL 诱导的破骨细胞生成，预防去卵巢诱导的骨质疏松症。
Phytomedicine. 2021 Jan;80:153377. doi: 10.1016/j.phymed.2020.153377. Epub 2020 Oct 12.
6
Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.冬凌草甲素通过抑制 ROS 介导的 NF-κB 和 NFATc1 活性减轻去卵巢诱导的骨丢失和 RANKL 诱导的破骨细胞形成。
Phytomedicine. 2024 Jul;129:155559. doi: 10.1016/j.phymed.2024.155559. Epub 2024 Mar 20.
7
Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation.培伐他汀通过调节破骨细胞吸收和成骨细胞形成来预防去卵巢诱导的骨质疏松症。
Biomed Pharmacother. 2021 Jul;139:111697. doi: 10.1016/j.biopha.2021.111697. Epub 2021 May 13.
8
Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.抗痴呆药物乙酰胆碱酯酶抑制剂通过抑制破骨细胞生成和骨吸收对骨质疏松性骨具有治疗作用。
J Cell Physiol. 2023 Aug;238(8):1823-1835. doi: 10.1002/jcp.31057. Epub 2023 Jun 19.
9
Zanthoxylum piperitum alleviates the bone loss in osteoporosis via inhibition of RANKL-induced c-fos/NFATc1/NF-κB pathway.花椒通过抑制 RANKL 诱导的 c-fos/NFATc1/NF-κB 通路缓解骨质疏松症的骨丢失。
Phytomedicine. 2021 Jan;80:153397. doi: 10.1016/j.phymed.2020.153397. Epub 2020 Oct 22.
10
Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.牛蒡苷通过抑制 RANKL 诱导的 ROS 和 NFATc1 激活来阻断破骨细胞生成和骨吸收。
Pharmacol Res. 2020 Sep;159:104944. doi: 10.1016/j.phrs.2020.104944. Epub 2020 May 23.

引用本文的文献

1
Coptidis Rhizoma Water Extract Attenuates RANKL-Induced Osteoclast Differentiation via MAPK, Akt, and NF-κB Pathways and Prevents Ovariectomy (OVX)-Mediated Bone Loss.黄连水提取物通过丝裂原活化蛋白激酶、蛋白激酶B和核因子κB信号通路减弱核因子κB受体活化因子配体诱导的破骨细胞分化，并预防去卵巢介导的骨质流失。
Int J Mol Sci. 2025 Sep 6;26(17):8707. doi: 10.3390/ijms26178707.

本文引用的文献

1
Denosumab and Mortality in a Real-World Setting: A Comparative Study.地舒单抗与现实环境中的死亡率：一项对比研究。
J Bone Miner Res. 2023 Dec;38(12):1757-1770. doi: 10.1002/jbmr.4930. Epub 2023 Dec 15.
2
Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis.朝藿定 C 可改善 RANKL 介导的破骨细胞生成和卵巢切除诱导的骨质疏松症。
Aging (Albany NY). 2023 Oct 3;15(19):10213-10236. doi: 10.18632/aging.205068.
3
CircFam190a: a critical positive regulator of osteoclast differentiation via enhancement of the AKT1/HSP90β complex.
环状 RNA 家族 190a：通过增强 AKT1/HSP90β 复合物促进破骨细胞分化的关键正调控因子。
Exp Mol Med. 2023 Sep;55(9):2051-2066. doi: 10.1038/s12276-023-01085-y. Epub 2023 Sep 1.
4
Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.近年来用于骨质疏松症临床治疗的小分子药物的研究进展：综述。
Eur J Med Chem. 2023 Nov 5;259:115654. doi: 10.1016/j.ejmech.2023.115654. Epub 2023 Jul 16.
5
Current and investigational medications for the treatment of sarcopenia.目前和正在研究用于治疗肌肉减少症的药物。
Metabolism. 2023 Dec;149:155597. doi: 10.1016/j.metabol.2023.155597. Epub 2023 Jun 20.
6
A Novel Role for RILP in Regulating Osteoclastogenesis and Bone Resorption.RILP 在调节破骨细胞生成和骨吸收中的新作用。
Lab Invest. 2023 May;103(5):100067. doi: 10.1016/j.labinv.2023.100067. Epub 2023 Jan 24.
7
Corylin ameliorates chronic ulcerative colitis via regulating the gut-brain axis and promoting 5-hydroxytryptophan production in the colon.柯里拉京通过调节肠-脑轴和促进结肠中5-羟色氨酸的产生来改善慢性溃疡性结肠炎。
Phytomedicine. 2023 Feb;110:154651. doi: 10.1016/j.phymed.2023.154651. Epub 2023 Jan 5.
8
Corylin inhibits the progression of Non-small cell lung cancer cells by regulating NF-κB signaling pathway via targeting p65.考利林通过靶向 p65 调控 NF-κB 信号通路抑制非小细胞肺癌细胞的进展。
Phytomedicine. 2023 Feb;110:154627. doi: 10.1016/j.phymed.2022.154627. Epub 2022 Dec 25.
9
Epigallocatechin-3-gallate inhibits osteoclastic differentiation by modulating mitophagy and mitochondrial functions.表没食子儿茶素没食子酸酯通过调节自噬和线粒体功能抑制破骨细胞分化。
Cell Death Dis. 2022 Oct 28;13(10):908. doi: 10.1038/s41419-022-05343-1.
10
Identification of Novel Genes for Cell Fusion during Osteoclast Formation.鉴定破骨细胞形成过程中细胞融合的新基因。
Int J Mol Sci. 2022 Jun 8;23(12):6421. doi: 10.3390/ijms23126421.